Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Sun Pharmaceutical Industries Limited

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Skin and Connective Tissue Diseases [C17]

Trial duration

27 May 2025 → ongoing

Decision date (initial)

2025-05-08

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

External identifiers

EU CT number

2024-515672-12-00

WHO UTN

U1111-1313-6005

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy

To evaluate the clinical efficacy of subcutaneous (SC) tildrakizumab compared to placebo, in subjects with moderate to severe genital psoriasis during a 16-week placebo-controlled Phase 3 study as measured by modified static Physician’s Global Assessment of Genitalia (sPGA-G) scores

Secondary objectives 1

1. To evaluate the clinical efficacy of SC tildrakizumab vs placebo at Week 16 on plaque psoriasis (as measured by body surface area [BSA], psoriasis area and severity index [PASI]), genital itch (as measured by genital psoriasis itch numerical rating scale [GPI-NRS]), and genital psoriasis symptoms (as measured by genital psoriasis symptoms scale [GPSS])

Conditions and MedDRA coding

Moderate to Severe Genital Psoriasis

Regulatory references

Scientific advice from competent authorities

Food And Drug Administration

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and provide written informed consent in accordance with institutional and regulatory guidelines
2. Age ≥18 years of age at the time of signing consent
3. Diagnosis of moderate to severe psoriasis of the genital area at Screening and baseline defined as modified sPGA-G score of ≥3.
4. Presence of non-genital plaque psoriasis (BSA ≥1 %) at both Screening and Baseline.
5. Presence of psoriasis of the genital area that is inadequately controlled with topical therapy or the subject is intolerant to topical therapy
6. Negative evaluation for TB within 4 weeks before initiating IMP, defined as a negative QuantiFERON test. Subjects with a positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests are allowed if they have all of the following: • no history of active tuberculosis (TB) or symptoms of TB, • a posteroanterior chest radiograph (with associated report available at the site) performed within 3 months of Screening with no evidence of active TB (or of any other pulmonary infectious diseases), • if prior latent TB infection, must have history of adequate prophylaxis (per local standard of care), • if presence of latent TB is established, then treatment according to local country guidelines must have been followed for 4 weeks, prior to dosing in the study at Visit 2 (Week 0). A maximum of 2 QuantiFERON tests of no more than 3 weeks apart are allowed. A re-test is only permitted if the first is indeterminate; the result of the second test will then be used
7. Physical examination within normal limits or clinically acceptable limits as per the investigator prior to the first dose of study medication. The investigator is encouraged to consult with the medical monitor (or appropriate designee) if there are questions regarding the significance of any out of range values.
8. For women of childbearing potential, a negative serum pregnancy test at Screening and a negative urine pregnancy test within 24 hours prior to the first dose of study medication
9. Subject must be in good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.

Exclusion criteria 23

1. Predominantly non-plaque forms of psoriasis specifically erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new-onset guttate psoriasis.
2. Live viral or bacterial vaccination within 4 weeks prior to baseline, or planned live viral or bacterial vaccination during the trial
3. Any significant organ dysfunction within 6 months prior to Screening that in the judgement of the Investigator places the subject at unacceptable risk for participation in a trial of an immunomodulatory agent
4. History of alcohol or drug abuse in the previous year in the opinion of the Investigator.
5. Known sensitivity to any of the products or any excipients to be administered during dosing (e.g. histidine, polysorbate 80, and sucrose).
6. Prior use of following therapies for treatment of psoriasis/psoriatic arthritis: a) Prior use of any investigational or approved drugs within 30 days or 5 half-lives, whichever is longer, prior to randomization. Prior use of Apremilast or other approved or investigational Janus kinase (JAK) inhibitors for the treatment of psoriatic arthritis and/or psoriasis which are not identified as permitted therapies within 5 half-lives or 15 days (whichever is longer) prior to IMP initiation. b) Use of etanercept within 4 weeks, infliximab within 8 weeks, and all other anti-TNF therapy within 3 months prior to IMP initiation c) Topical therapy within 2 weeks of randomization [including but not limited to topical Phosphodiesterase-4 enzyme (PDE-4) inhibitors (e.g. roflumilast, crisaborole) topical corticosteroids, topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol for body lesions; coal tar, salicylic acid preparations, or medicated shampoos for scalp lesions]. d) Conventional systemic therapy for psoriasis within 4 weeks prior to randomization (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, or fumaric acid esters). e) Leflunomide within 6 months prior to randomization. f) Phototherapy treatment of body within 4 weeks prior to randomization (i.e., ultraviolet B, psoralen and ultraviolet A radiation). g) Any prior use of biologics, approved or investigational, such as secukinumab, ustekinumab, ixekizumab, brodalumab, or any drugs targeting interleukin (IL)-17, IL-23, or the IL-12/IL- 23-shared p40 molecule or any biosimilars for each for the treatment of psoriasis, psoriatic arthritis, or any other indication that could impact the assessment of psoriasis h) Prior use of B-cell depleting agent or T-cell inhibitor within 12 months of Screening
7. Currently enrolled in any investigational study
8. Planned surgical intervention between baseline and the Week 16 evaluation for a pre-treatment condition.
9. Active infection or history of infections as follows: a. any active infection (bacterial, fungal or viral) for which systemic anti-infectives were used within 28 days prior to first IMP dose, with the last dose having been received within 7 days of Screening, b. a serious infection, defined as requiring hospitalization or intravenous (IV) anti-infectives within 8 weeks prior to the first IMP dose, with the last dose having been received within 7 days of Screening, c. recurrent or chronic infections, e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis, or other active infection that, in the opinion of the Investigator, might cause participation in this study to be detrimental to the subject
10. Any concurrent medical condition or uncontrolled, clinically significant systemic disease (e.g., renal failure, heart failure, hypertension, liver disease, diabetes, or anemia) that, in the opinion of the Investigator, could jeopardize subject safety or compliance with the protocol.
11. Myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to the first IMP dose.
12. Women of childbearing potential who are pregnant, intend to become pregnant during the trial or within 17 weeks of completing the trial, or are lactating.
13. Positive human immunodeficiency virus (HIV) test result, hepatitis B virus (HBV), or hepatitis C virus (HCV) testing The following algorithm shall be followed for all subjects to evaluate this exclusion criteria: a. Subjects with positive anti-HIV antibody shall be excluded from the study b. Subjects with a Hepatitis B surface antigen (HBsAg) positive test will be excluded from the study. c. Subjects with a HBsAg negative test shall be tested for Hepatitis B core antibody (Anti-HBc). Subjects with negative Anti-HBc can be included in the study. Subjects with positive Anti-HBc shall further be tested for HBV - deoxyribonucleic acid (HBV-DNA). Subjects testing negative for HBV-DNA shall be included in the study. Subjects testing positive for HBV-DNA shall be excluded from the study. In the event the HBV-DNA test cannot be performed, the subject shall NOT be considered eligible for this study. d. Subjects with HCV antibody non-reactive will be included in the study. Subjects with HCV antibody reactive, shall be tested for HCV - ribonucleic acid (HCV RNA). If tested negative, subject can be included in the study. Subjects with HCV-RNA positive shall be excluded from the study. In the event the HCV-RNA test cannot be performed, the subject shall NOT be considered eligible for this study.
14. Any active malignancy (including but not limited to cutaneous basal cell carcinoma, squamous cell carcinoma or melanoma).
15. Any prior malignancy within 5 years from Screening (excluding successfully treated and cured cutaneous basal cell carcinoma or squamous cell carcinoma, or in situ breast ductal carcinoma).
16. Laboratory abnormalities at Screening, including any of the following: • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal (ULN), • Creatinine ≥ 2 times the ULN • Serum direct bilirubin ≥ 1.5 mg/dl • White blood cell (WBC) count < 3.0 x 103/μL • Platelet count ≤ 100,000/µl • Hemoglobin (Hb) < 10.0 g/dl • Any other laboratory abnormality, that is considered clinically significant by the Investigator and which, in the opinion of the Investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results
17. Significant risk of suicidality at the Screening assessment based on the Investigator’s judgment or, if appropriate, as indicated by: a response of “yes” within the last 6 months to question 4 or 5 in the suicidal ideation section, or any response in the behavioral section of C-SSRS
18. Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon entering the study and through 17 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 17 weeks following final administration of IMP. A follicle-stimulating hormone (FSH) test should be performed to confirm menopause for those women with no menses for less than 1 year.
19. Previous enrollment (randomized and received IMP) in this study.
20. Subject has evidence of skin conditions that would interfere with clinical assessments.
21. Subject has prolonged sun exposure or use of tanning booths or other ultraviolet light sources
22. Presence of excessive hair, tattoos, pigmentation, extensive scarring, pigmented lesions, or sunburn in the treatment area, which could make the affected plaque psoriasis BSA difficult to visualize
23. Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest could arise

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Tildrakizimab vs placebo at week 16: Proportion of subjects with a modified sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline

Secondary endpoints 6

1. Proportion of subjects, with a baseline score of ≥4, who achieve at-least 4-point improvement in weekly average of GPI- NRS
2. Mean change from baseline in the affected BSA
3. Change from baseline in GPSS total score and individual items scores
4. Proportion of subjects with PASI 75 response (≥ 75% reduction from baseline in PASI score)
5. Proportion of subjects with PASI 90 response (≥ 90% reduction from baseline in PASI score)
6. Proportion of subjects with PASI 100 response (100% reduction from baseline in PASI score), insubjects with BSA <10%

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sun Pharmaceutical Industries Limited

Sponsor organisation

Sun Pharmaceutical Industries Limited

Address

1 Plot No 201 B, Western Express Highway, Goregaon East Western Express Highway Goregaon East

City

Mumbai

Postcode

400063

Country

India

Scientific contact point

Organisation

Sun Pharmaceutical Industries Limited

Contact name

Tushar Nishandar

Public contact point

Organisation

Sun Pharmaceutical Industries Limited

Contact name

Punit Patel

Third parties 6

Locations

3 EU/EEA countries · 19 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 90 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

4 submissions — initial application plus substantial / non-substantial modifications